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Background: Toxoplasmosis is a disease caused by Toxoplasma gondii and at least one-third of the world’s
population has detectable T. gondii antibodies. The seroprevalence of T.gondii ranges from 15% to 50% among the
Mexican general population. The aim of this work was to determine the mean prevalence and weighted mean
prevalence of T. gondii infection, and to evaluate the epidemiological transition of infection in Mexico.
Methods: Pub Med, Lilacs, Medline, Latindex, Google Scholar data bases were searched to retrieve reports from
1951 up to 2012 regarding prevalence data, diagnostic tests and risk factors of infection among the adult
population. Data collection and criteria eligibility was established in order to determine the crude prevalence
(proportion of positive cases) of each study, together with weighted population prevalence according to individual
research group categories to limit the bias that may impose the heterogeneous nature of the reports. A Forest Plot
chart and linear regression analysis were performed by plotting the prevalence of infection reported from each
study over a period of sixty years.
Results: A total of 132 studies were collected from 41 publications that included 70,123 individuals. The average
mean prevalence was 27.97%, and weighted mean prevalence was 19.27%. Comparisons among different risk
groups showed that the weighted prevalence was higher in women with miscarriages (36.03%),
immunocompromised patients (28.54%), mentally-ill patients (38.52%) and other risk groups (35.13%). Toxoplasma
infection among the Mexican population showed a downward trend of 0.1%/year over a period of sixty years that
represents a 5.8% reduction in prevalence.
Conclusions: This analysis showed a downward trend of infection; however, there are individuals at high risk for
infection such as immunocompromised patients, mentally-ill patients and pregnant women. Further research is
required to provide better prevention strategies, effective diagnostic testing and medical management of patients.
Educational efforts are required to avoid the transmission of infection in populations that cannot be controlled by
drugs alone.
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Toxoplasmosis is a disease caused by Toxoplasma gondii
(T. gondii). It was described in a North African rodent
(Ctenodactylus gondii) by Nicolle and Manceaux in 1908
[1]. The T. gondii is an obligate intracellular parasite
with a complex life cycle, in which homeothermic animals,
including humans are capable of acting as intermediate
hosts. Humans acquire the parasite by the oral route
through the consumption of undercooked meat contami-
nated with cysts, food products (vegetables and fruits) or
water contaminated with oocysts [1,2]. Other routes of
transmission are organ transplantation [3,4], blood trans-
fusion [5] and congenital transmission. Butchers, slaugh-
terhouse workers and laboratory personnel that handle
cultures and animal models with this parasite are also at
risk. However, for the majority of the human population,
transmission generally occurs by any of the routes afore-
mentioned [6].
T. gondii is found worldwide because a large variety of
animals may harbor the parasite and maintain its dis-
semination. Its broad geographic location is related to
several factors, such as contact with infected cat feces
and ingestion of mature oocysts [7], food habits and
variations in climate. The later has a significant influence
on the habitat of T. gondii; for instance, an increase in
ambient temperature and precipitation can change the
humidity of the soil, so that the sporulated oocysts
remain viable in the moist environment for a longer
period [8,9].
T. gondii is considered as the most prevalent parasitic
zoonotic disease worldwide [10], since at least one-third
of the world’s population is infected [11]. Infections
caused by T. gondii are more frequent in temperate zones
than in cold ones; thus, France has the highest preva-
lence of 90%, whereas the lowest prevalence is found
in Alaska with only 1%. However, global warming has
caused an increase of T. gondii infections in different
regions of the world as a result of changing environ-
mental conditions [8].
The mean prevalence of T. gondii infection among the
Mexican general population is 50%; however, there are
variations that depend on climate and humidity. Several
risk groups have been identified with high prevalence of
infection such as cat owners, people who consume raw or
undercooked meat, immunocompromised patients and
those that undergo organ transplantation [3,4]. Fur-
thermore, we recently carried out a meta-analysis on
reports of toxoplasmosis among Mexican newborns. The
weighted prevalence in 4833 asymptomatic newborns
was 0.616%, whereas, among 895 symptomatic newborns,
the weighed prevalence was 3.02% [12].
Diagnostic testing for toxoplasmosis can be done by
staining body fluids or mouse inoculation to see if Toxo-
plasma parasites develop. Skin test antigen (toxoplasmin)(STA), and serological procedures such as the Comple-
ment Fixation Test (CF), Latex Flocculation Test (LF),
Sabin and Feldman (SF), Indirect Haemagglutination
Test (IHA), Indirect Immunofluorescence assay (IFI),
and Enzyme-linked immunosorbet assay (ELISA) have
been employed to detect specific antibodies in screening
programs and also as adjuncts to the diagnosis of acute
toxoplasmosis. More recently other methods have been
developed such as Western-blot and detection of DNA
with polymerase chain reaction (PCR) [1,4].
Treatment for human toxoplasmosis is highly import-
ant for immunocompromised patients or acutely infected
pregnant women. Various pharmacological agents are
available such as pyrimethamine alone or combined with
sulfadiazine. Atovaquone has been used as a second
course of treatment for retinochoroiditis. Azithromycin
is used as an alternative in the treatment of ocular and
cerebral toxoplasmosis in AIDS patients, as well as, for
active, non-vision-threatening toxoplasmic retinochoroi-
ditis with satisfactory results [1,13,14].
The purpose of this systematic review and meta-analysis
was to evaluate the seroprevalence of toxoplasmosis and
its relationship with different risk factors. The under-
standing of these relationships can aid in the analysis of
the epidemiological pattern of disease among different




This study was approved by the Ethical Committee of the
Health Sciences Center of the University of Guadalajara
# C.I.100-2012.
Database search
Five databases were searched (Pub Med, Lilacs, Medline,
Latindex and Google Scholar) from January to June of
2012. The following limits were applied: published
January 1951 to 2012, the first case of human T. gondii
infection was reported in an 11-month old girl from
the Pediatric Hospital at Mexico City in 1950 [15],
written in English or Spanish and undertaken in adults.
The search terms were “infection with Toxoplasma”,
“toxoplasmosis”, “epidemiology”, “risk factors”, “infection
by T. gondii, Mexico” “anti-Toxoplasma antibodies”
alone or combined.
Data collection
All retrieved studies were studied carefully by two inves-
tigators (GRML and BR). The extracted data included:
year of publication, characteristics of the study popula-
tion, location of the study, sample size, number of cases,
diagnostic test and risk factors. Abstracts were included
if considered acceptable, but were not included in the
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publications and textbooks were also examined to iden-
tify studies not retrieved by the original search.
Data analysis
The crude prevalence data and the weighted prevalence
were calculated for each study (Table 1) [16-59]. Seven
different types of diagnostic tests were identified during
the literature search. Table 2 summarizes their main
characteristics, sensitivity and specificity, and their time-
line of employment in Mexico. Study groups were also
stratified according to categories alone (Table 3) or by
combining the risk group and diagnostic test used in
each study [60-66] (Table 4).
The study groups were divided into: 1) Individuals
with risk factors were designated as high risk groups that
included: women who had had abortions, immunocom-
promised patients with AIDS or HIV, leprous people,
patients with neurological disorders, pet-cat, owners and
slaughterhouse workers; 2) Individuals without risks fac-
tors were designated in low risk groups: blood donors,
general population and normal pregnant women.
Statistical methods
Crude prevalence
The crude prevalence of each study group was estimated
to assess the amount of affection by the disease expressed
in percentage of positives cases in relation to all cases
analyzed. It was calculated as the number of positive
cases divided by the sample size of the cohort in each
study group.
Weighted population prevalence (WP)
The assessment of the prevalence of T. gondii of the dif-
ferent study groups was estimated by using the weighed
population prevalence, given that not all the studies
included the same number of individuals. This strategy
restricts the bias that may impose the heterogeneous
nature of the reports, and has proven to be valid when
combining a number of studies with inherent hetero-
geneity in sample size and effects [67].
Each crude prevalence was multiplied by a “weight”,
which was proportional to the number of subjects
included in the sample, i.e., in large samples, the preva-
lence found outweighs that of small samples. This preva-
lence is obtained by summing the product of the
prevalence for its “weight” of the sum of the “weights”.
This estimate is more accurate than the overall crude
prevalence to estimate the true prevalence of a cumula-
tive set of groups. The formula to calculate the popula-
tion prevalence (weighed prevalence, WP) of T. gondii





1/vi as explained by Borenstein
et al. [68].Definitions
i = Number of studies in each group. Ni = Total number
of cases in each study, Ai = Number of positive cases
from each study, (Ni-Ai) is the number of negative cases
in each study. The risk of infection as a proportion in
each study (pi) was calculated as Ai/Ni. The variance of
each study (vi) was calculated as Ai (Ni-Ai)/Ni3. The
standard error (SEi) of each study was estimated as √ vi.
The total population variance (V) was estimated as
1/
P
1/vi. The standard error of the population was
calculated as SE = √V. The confidence interval (C.I.95%)
for the population prevalence was obtained by P + 1.96
SE (upper limit) and P-1.96 EE lower limit. The probabil-
ity that the prevalence could be different from zero was
calculated with a Z test, Z = P/SE.
Forest plot
A Forest Plot chart was built in order to provide a
comprehensive analysis of the studies included in the
meta-analysis according to its odd ratio and confidence
interval (CI) [68].
Linear regression analysis
A bivariate linear regression analysis was conducted to
determine the relationship between the seroprevalence
of Toxoplasma infection over time. The regression coef-
ficient was calculated by the equation (y = a + b x),
a = ordinate of origin, b = slope and the R2 and p were
obtained with the SPSS program (Version 18). The epi-
demiological behaviour of the prevalence of Toxoplasma
infection was estimated by plotting the year of each
publication date (independent variable) starting at year
1951 until 2012 versus the relative prevalence (dependent
variable) reported in each study [68].
Results
From the five databases, a total of 45 publications were
eligible that included 132 studies and 70,123 individuals,
and 19,262 positive cases as shown in Table 1. As shown
in Table 3, most of the studies were carried out in low
risk groups, such as, the general population (n = 90
studies) followed by pregnant women (n = 12), with the
least number of studies in blood donors (n = 4). In the
high-risk groups, relatively fewer studies have been car-
ried out; women with miscarriage (n = 3), immuno-
compromised patients (n = 7), mentally-ill patients (n = 4),
other risk groups (n = 5) and patients with nonrelated
comorbidity (n = 7). To the best of our knowledge, all
the studies included in this meta-analysis had a cross-
sectional design and were aimed to identify the preva-
lence of T. gondii antibodies in a cohort. No prospective
or follow-up studies aimed to seek seroconversion or
self-reported results were detected.
Table 1 Publications included for meta-analysis with diagnostic methods and population characteristics








1 1951 BiagiF. Tamaulipas Tampico STA GP 231 108 47 [16]
2 1952 Biagi F. México Mexico STA IC 155 58 37.4 [49]
3 1952 Bustos C. Veracruz Orizaba STA GP 86 31 51 [17]
4 1953 Biagi F. Campeche Escarcega STA GP 132 76 56.8 [18]
5 1953 Varela G. Estado de
Mexico
Toluca STA GP 500 81 16 [19]
6 Varela G. Mexico México STA CM 116 19 16 [19]
7 Varela G. Mexico México STA CM 47 7 14.8 [19]
8 Varela G. Mexico México STA CM 102 13 12.7 [19]
9 Varela G. Zoquiapan STA IC 107 13 14 [19]
10 1954 Gutierrez E.B. México México CFT MI 58 14 24.14 [53]
11 1955 Varela G. Mexico México SF GP 60 16 26.7 [20]
12 Varela G. Michoacan N.E. SF GP 22 6 27.3 [20]
13 Varela G. Mexico México SF GP 104 39 37.5 [20]
14 Varela G. Oaxaca Oaxaca SF GP 276 96 34.8 [20]
15 Varela G. Tamaulipas N.E. SF GP 230 90 39 [20]
16 Varela G. Yucatan N.E. SF GP 17 11 64.7 [20]
17 Varela G. Distrito
federal
Mexico SF MI 91 54 59 [20]
18 Varela G. Puebla N.E. SF GP 44 41 93.2 [20]
19 1957 Biagi F. México Ixtapalapa, D.F. STA GP 272 37 13.6 [21]
20 1961 Varela G. Baja, California Mexicali SF GP 73 26 35.9 [22]
21 Varela G. Chihuahua Chihuahua SF GP 12 3 25 [22]
22 Varela G. México Distrito Federal SF GP 2,463 783 31.8 [22]
23 Varela G. Hidalgo Apan SF GP 409 117 28.6 [22]
24 Varela G. Estado de
Mexico
Toluca SF GP 64 15 23.4 [22]
25 Varela G. Michoacan Morelia SF GP 35 11 31.42 [22]
26 Varela G. Morelos Various SF GP 208 54 25.96 [22]
27 Varela G. Nayarit Tepic SF GP 112 25 22.3 [22]
28 Varela G. Oaxaca Oaxaca and
Tuxtepec
SF GP 546 107 19.59 [22]
29 Varela G. Puebla Puebla SF GP 170 61 35.9 [22]
30 Varela G. Queretaro Various SF GP 90 33 36.66 [22]
31 Varela G. Sinaloa Culiacan SF GP 311 109 35 [22]
32 Varela G. Sinaloa Mazatlan SF GP 100 16 16 [22]
33 Varela G. Tabasco Macuspana SF GP 108 38 35.2 [22]
34 Varela G. Tamaulipas Ciudad Victoria SF GP 220 39 17.7 [22]
35 Varela G. Tamaulipas Nuevo Laredo SF GP 100 28 28 [22]
36 Varela G. Tlaxcala Tlaxcala SF GP 594 144 24.2 [22]
37 Varela G. Veracruz Boca del Rio SF GP 93 36 38.7 [22]
38 Varela G. Veracruz Soconusco SF GP 121 39 32.2 [22]
39 Varela G. Veracruz Veracruz SF GP 125 30 24 [22]
40 Varela G. Yucatan Merida SF GP 17 11 64.7 [22]
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Table 1 Publications included for meta-analysis with diagnostic methods and population characteristics (Continued)
41 1962 Carrillo C. México Mexico SF BD 232 73 31.4 [46]
42 1965 Espinosa de los Reyes VM, México Mexico SF PW 329 112 34 [37]
43 1966 Roch E. Distrito
Federal
México SF MW 2,320 815 35.13 [44]
44 1966 Roch E. Mexico All States SF GP 14,869 4,411 30 [23]
45 1972 Goldsmith RS. Oaxaca Puerto Escondido IHA GP 159 2 1.26 [24]
46 1972 Goldsmith RS. Oaxaca Mixteca Alta IHA GP 114 0 0 [24]
47 1972 Goldsmith RS. Oaxaca Ixtlan IHA GP 48 2 4.2 [24]
48 1972 Goldsmith RS. Oaxaca Región del Valle IHA GP 150 5 3.3 [24]
49 1972 Goldsmith RS. Oaxaca Tehuantepec IHA GP 137 18 13 [24]
50 1974 Biagi F. Mexico México FL WP 367 73 19.9 [35]
51 1986 Fernandez Terrano Tabasco Region de los
Rios
IFI-G WP 125 75 60 [36]
52 1989 Galvan-Ramirez ML. Jalisco IFI-G GP 807 25 3.1 [25]
53 1989 Zavala-Velazquez J. Yucatan Merida IFI-G MW 100 47 47 [45]
54 1991 Goldsmith RS. Oaxaca 60 municipalities IHA GP 3,229 124 3.8 [26]
55-86 1991 Velasco- Castrejon O. Mexico All states IFI-G GP 29,279 9,371 32 [27]
87 1995 Galvan-Ramirez ML. Jalisco Guadalajara ELISA-G PW 350 122 34.9 [39]
88 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G MW 105 48 44.9 [39]
89 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G PW 50 13 26.01 [39]
90 1997 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G IC 39 27 69.2 [50]
91 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G IC 53 19 35.8 [50]
92 1997 Tay J. Distrito Fed. México ELISA-G MI 328 125 38 [54]
93 1998 Gongora R. Yucatan Mérida ELISA-G IC 95 45 47 [47]
95 Gongora R. Yucatan Mérida ELISA-G BD 100 69 69 [47]
93 1999 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G ORG 59 38 64 [7]
96 2000 Kelso Santos E. Nuevo Leon Monterrey ELISA-G GP 400 82 20.5 [29]
97 2003 Jaramillo P.J. Estado de
Mexico
Toluca ELISA-G PW 372 47 12.61 [40]
98 2004 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G PW 30 14 47 [38]
99 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G PW 30 13 43 [38]
100 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G PW 60 17 28.3 [38]
101 2005 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G BD 359 104 29 [5]
102 2006 Alvarado-Esquivel C. Durago Guadalajara ELISA-G PW 343 21 6.1 [41]
103 2007 Alvarado-Esquivel C. Durango Durango ELISA-G BD 432 32 7.4 [48]
104 2008 Alvarado-Esquivel C. Durango Durango ELISA-G ORG 90 19 21.1 [58]
105 Alvarado-Esquivel C. Durango Durango ELISA-G ORG 83 7 8.4 [58]
106 2008 Alvarado-Esquivel C. Durango Durango ELISA-G GP 187 67 35.8 [30]
107 2008 Alvarado-Esquivel C. Durango Durango ELISA-G GP 121 20 16.5 [30]
108 2008 Alvarado-Esquivel C. Durango Durango ELISA-G GP 155 23 14.8 [30]
109 2008 Galvan-Ramirez ML. Jalisco Guadalajara ELISA-G ORG 145 104 72 [6]
110 2009 Alvarado-Esquivel C. Durango Guadalajara ELISA-G PG 439 36 8.2 [42]
111 2009 Cañedo-Solares I. Distrito
Federal
Mexico ELISA-G PG 100 30 30 [43]
112 2010 Alvarado-Esquivel C. Durango Durango ELISA-G GP 248 22 8 [31]
113 2010 Alvarado-Esquivel C. Durango Durango ELISA-G GP 61 4 6.6 [56]
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Table 1 Publications included for meta-analysis with diagnostic methods and population characteristics (Continued)
114 Alvarado-Esquivel C. Durango Durango ELISA-G GP 203 17 8.4 [56]
115 Alvarado-Esquivel C. Durango Durango ELISA-G GP 168 10 6.6 [56]
116 2010 Alvarado-Esquivel C. Durago Durango ELISA-G GP 152 46 30 [31]
117 2010 Galvan-Ramirez ML Jalisco Guadalajara ELISA-G GP 174 30 17.8 [28]
118 2010 Alvarado-Esquivel C. Durango Durango ELISA-G CM 85 7 8.2 [51]
119 Alvarado-Esquivel C. Durango Durango ELISA-G CM 50 5 10 [51]
120 Alvarado-Esquivel C. Durango Durango ELISA-G CM 234 28 12 [51]
121 Alvarado-Esquivel C. Durango Durango ELISA-G IC 103 7 6.8 [51]
122 2011 Alvarado-Esquivel C. Durango Durango ELISA-G ORG 124 8 7 [57]
123 2011 Alvarado-Esquivel C. Durango Durango ELISA-G MI 50 10 20 [55]
124 2011 Alvarado-Esquivel C. Durango Durango ELISA-G GP 150 8 5.3 [32]
125 2011 Alvarado-Esquivel C. Durango Durango ELISA-G IC 75 10 13.3 [52]
126 Alvarado-Esquivel C. Durango Durango ELISA-G GP 150 16 10.7 [52]
127 2011 Alvarado-Esquivel C. Durango Durango ELISA-G GP 1,101 76 6.9 [59]
128 Alvarado-Esquivel C. Durango Durango ELISA-G CM 55 9 16.4 [59]
129 2011 Alvarado-Esquivel C. Durango Durango ELISA-G GP 974 59 6.1 [32]
130 2012 Alvarado-Esquivel C. Durango Durango ELISA-G GP 133 11 8.3 [33]
131 Alvarado-Esquivel C. Durango Durango ELISA-G GP 266 14 5.3 [33]
132 2012 Alvarado-Esquivel C. Durango Durango ELISA-G GP 156 35 22.4 [34]
Total 70,123 19,262
Skin test antigen (toxoplasmin) (STA); Complement Fixation Test (CF); Latex Flocculation Test (LF); Sabin & Feldman (SF); Indirect Haemagglutination Test (IHA);
Enzyme-linked immunosorbet assay and type of antibody detected (ELISA-G), Indirect Immunofluorescence assay and type of antibody detected (IFI-G); General
Population (GP); Pregnant Women (PW); Blood Donors (BD); Patients with Comorbidity (CM); Immunocompromised patients (IC); Women with Miscarriages (MW);
Mentally-ill patients (MI); Other risk groups (ORG).
Table 2 Diagnostic methods
Diagnostic test Fundament Sensitivity Specificity Timeline References
Skin test antigen (STA Type IV cell-mediated hypersensitivity
reaction against the T.gondii antigen.
80% 70% 1950-1951 [16-19,21,49]
Sabin and Feldman
Dye Test (SF).
The gold standard. A dye test in which the
serum antibodies alter the staining pattern
of the T. gondii tachyzoites.
96% 98% 1955-2005 [20,22,23,37,44,46]
Complement Fixation
Test (CF).
Antigen-antibody complexes are formed
and detected by using a standard system
with hemolisin and complement
97.1% 64.5% 1954-1982 [53]
Látex Flocculation
Test (LF).
This test uses latex particles for
antigen-antibody flocculation.
No reported. 1974 [35]
Indirect Fluorescent
Antibody Test (IFI).
Tachyzoites are fixed on a slide and
exposed to test serum, then washed
and exposed to a standard antibody
labeled with fluorescent dye.




This test uses sheep red cells exposed
to tannic acid and then to the soluble
antigen fixed at 37 °C.




The ELISA detects T. gondii immunoglobulin
IgG e IgM in serum and other body fluids
with antibodies marked with peroxidase
and fosfatase enzymes
100% 98.4% 1995 to date [6,7,29-34,39-43,47,48,50-52,55,56]
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General population 90 61536 16855 27.39 20.26 18.78-19.36 [16-24,34,51,52,55,56,58,59]
Pregnant Women 12 2595 573 22.08 15.62 14.30-16.93 [35-43]
Blood Donors 4 1123 278 24.76 17.035 15.03-19.03 [5,46-48]
Patients with comorbidity 7 689 88 12.77 12.27 9.83-14.72 [19,51,59]
High Risk Groups
Women with miscarriages 3 2525 910 36.03 35.96 34.1-37.83 [39,44,45]
Immunocompromised patients 7 627 179 28.54 20.2 17.35-23.05 [19,47,49-52]
Mentally-ill patients 4 527 203 38.52 37.24 33.24-41.26 [20,53-55]
Other risk groups 5 501 176 35.13 21.88 19.0-24.76 [6,7,57,58]
Total 132 70,123 19,262
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General population
Most of the studies were carried out in low risk groups
such as the general population (90 studies) that gave a
total of 61,536 people tested for T. gondii infection. The
WP was 20.26% (CI95%18.78% – 19.36%) with a variance
of 0.0002% and a standard error of 0.1463%, Z = 130.391
and p <0.001 (Table 3).
Pregnant women
In this study group, 12 publications included 2,595 preg-
nant women. The WP was 15.62% (CI95%14.30%-
16.93%), with a variance of 0.0045% and standard error
of 0.67%, Z = 23.313 and p <0.001 (Table 3).
Blood donors
In 4 studies, a total of 1123 blood donors were tested.









with Risk - STA 4 480 103
without Risk -STA 6 1268 340
without Risk-LF 1 367 73
without-risk CF 1 58 14
without Risk-SF 32 22245 6674
with Risk-SF 1 2320 815
without Risk-IFI-G 36 29997 9597
with Risk-IFI-G 5 1295 224
without Risk-IHA 6 3837 151
with Risk-ELISA-G 18 1963 523
without Risk-ELISA-G 22 6293 748
Total 132 70,123 19,262
Complement Fixation (CF), Skin test antigen toxoplasmin (STA), Latex Floculation (L
Fluorescence (IFI), Enzyme-linked immunosorbet assay (ELISA). All prevalences calcuvariance of 0.00104% and standard error of 1.0213%,
Z = 16.679 and p <0.001 (Table 3).
Patients with comorbidity
In 689 cases from seven studies, a WP of 12.27%
(CI95% 9.83 – 14.72) was found with a variance of 0.0155%,
standard error of 1.2463%, Z = 9.85 and p <0.001 (Table 3).
Meta-analysis in high-risk groups
Women with miscarriages
In 3 studies, 2595 women were tested. The WP was
35.96% (CI95% 34.10% - 37.83%) with a variance of
0.0091% and standard error of 0.9532%, Z = 37.73 and
p <0.001 (Table 3).
Immunocompromised patients
In this study group, 627 patients from seven studies were









21.45 13.39 10.35 16.44
22.81 22.48 20.32 24.65
19.89 19.89 15.8 23.97
24.14 22.16 13.64 35.15
30 30 29.4 30.59
35.13 35.12 33.18 37.18
31.99 29.3 28.81 29.79
16.77 5.58 4.44 6.77
3.94 2.63 1.24 4.02
26.64 17.66 16.17 19.15
11.89 8.92 8.24 9.6
F), Sabin and Feldman (SF), Indirect Hemaglutination (IHA), Indirect
lated by meta-analysis were statistically significant (p < 0.001).
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Z = 13.90 and p <0.0001 (Table 3).
Mentally-ill patients
A total of 527 mentally-ill patients were included from
four studies. The WP was 37.24% (CI95% 33.24% - 41.26%)
with a variance of 0.0994% and standard error of 3.15%,
Z = 11.43 and p <0.001 (Table 3).
Other risk groups
In 501 cases from five studies, a WP of 21.88%
(CI95% 19.00% - 24.76%) was found with a variance of
0.0215%, standard error of 1.46%, Z = 14.91 and p <0.001
(Table 3).
Weighted prevalence by diagnostic test and risk factors
In order to determine, if the prevalence of T. gondii was
based on the diagnostic test, the study groups were
adjusted by diagnostic test and risk factors reported.
Only the studies that used the SF assay and ELlSA
showed a correlation between the low and high risk.
Interestingly, the rest of the diagnostic tests showed a
lower prevalence, although it is noteworthy to mention
that the difference may be due to the number of cases in
the risk group categories (Table 4).
Epidemiological transition of Toxoplasma infection in
Mexico
Figure 1 illustrates the Forest Plot analysis of the WP
(CI95%) of each study included in this meta-analysis. The
linear regression analysis of Toxoplasma infection in the
Mexican population over a time span of 60 years showed
a downward trend of 0.1%/year that represents anFigure 1 Epidemiological transition of the T. gondii infection from 19
prevalence of Toxoplasma gondii infection reported in each study gro
was not statistically significant (NS).overall 5.8% reduction of infection (R2 = 0.0354 and F
(1) =4.802, p > 0.05) that was not statistically significant
(Figure 2).
Discussion
The questions that led us to achieve this study were if
Mexico had a significant prevalence of toxoplasmosis,
and if there have been changes in the epidemiology of
this disease from 1951 to date. Five databases were
searched, and 132 studies were selected involving 70,123
individuals and 19,262 positive cases.
This study showed that the WP of toxoplasmosis in
Mexico was 20.26%, which is relatively low compared to
the mean prevalence of 32% reported in 1991 [27]. This
can be explained if we note that variations between
methodologies can result in heterogeneity of the estima-
tions. However, despite this situation, at least 20.26% of
Mexicans may have been exposed to toxoplasmosis.
Between 1951 and 1958, the STA was an appropriate
test since, at that time, it was a rapid and sensitive assay
for epidemiological studies. It did not give cross-reactions
with other parasites, but it did make a fair amount of
false-negatives in mild infections. This was one of its dis-
advantages when used for a survey in the general popula-
tion in Tamaulipas, Campeche and Mexico City (1953).
The WP was 21.31% in 11 study groups with 1846 cases
[16-20]. Since only one study was performed by the
FL test with 367 individuals, and another study included
58 cases tested by fixation complement, we were not able
to compare these results against the SF or IFI assays.
The SF test was used in epidemiological studies carried
out between 1961 and 1966. The CP and WP was 30%
and 35.12%, respectively [23]. The advantage of this test54 to 2012, (―) Linear regression and triangle (♦) is the individual
up. The decrement in the prevalence rate was 0.1%/year. The R2 value
Figure 2 Weighted prevalence of Toxoplasma gondii infection from 132 studies. Forest plot shows event numbers, total numbers and
confidence intervals for all study groups included in the meta-analysis. The triangle (♦) represents the prevalence of each study and (⊺ ⊥) are
intervals of confidence.
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although the disadvantage is that it requires live para-
sites. The global prevalence during that time was 14.92%,
which is closer, to the prevalence of 8.26% aforemen-
tioned. In the same period, the IFI test was introduced
and was then used in the largest survey carried out in
Mexico (1992) with 29, 279 people with a mean preva-
lence of 32.0% [27]. The meta-analysis of all tests per-
formed with IFI was 29.32%, because the majority of
studies have used this method (31,412 cases).
In the 80s, the ELISA methods were introduced with
higher sensitivity and specificity that reduced the number
of cross-reactions. Interestingly, the WP was lower, ran-
ging from 8.92% to 17.66%, which may have been caused
by the lower number of cases, (8256 cases), less than
one-third of the studies, when compared to the 26,751
cases tested with SF and the 30,485 cases with IFI.
The general population involved 61,536 cases with a
WP of 20.26%, while the mean prevalence was reported
as 32% in 1991 [27]. This discrepancy may be caused
by the differences in the diagnostic methods that are
then adjusted when the weighted prevalence was esti-
mated [27].
Pregnant women presented a WP of 15.62% with an
upper limit of 16.93% that is closer to the general popu-
lation prevalence (20.26%), which is reasonable since
these women did not have obstetric complications. These
values were lower compared to 45.8% and 30.5%,respectively for specific IgG antibodies detected by the
Sabin-Feldman dye test in two separate studies among
pregnant women [69], however, our results were higher
than 0.6% among pregnant women in Norway [70].
In the four studies performed in blood donors, the WP
was 17.03% among 1123 cases. This prevalence is also
closer to the general population prevalence, despite that
each one of them was carried out with different diag-
nostic tests (one with SF [46], one not reported [47], one
with IFAT [5] and one with ELISA, respectively [48]).
Regarding the blood donors group, this group has a
lower WP when compared to the general population.
Transfusion Medicine guidelines have pronounced that
donated blood should be screened for toxoplasmosis,
because of the potential risk for blood receptors receiving
transfusions from subjects in the acute phase of infec-
tion. Therefore, testing of toxoplasmosis in blood dona-
tions should be mandatory in the country [5,46-48].
Three studies performed in Mexico were in women
with miscarriages having primary infection during preg-
nancy. There were clear differences between the WP of
pregnant women 15.62% whereas those with miscarriages
had 35.96% (p <0.05). These results are concordant with
other studies that have shown an association between
high prevalence of miscarriages and Toxoplasma infec-
tion [39,44,45].
Another risk group was the immunocompromised
patients. Among 627 cases, the WP of 20.2% was the
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that the patients were diagnosed by different methods,
and two studies performed in Durango had the lowest
prevalence [47,49-52].
The highest WP was 37.24% in the mentally-ill
patients, at least 18.27% higher than the general popula-
tion [55]. Several authors have reported a high prevalence
of Toxoplasma antibodies in patients with schizophrenia,
although other factors such as genetic may be present
in the schizophrenia, different reports have shown that
Toxoplasma is somehow associated with cases of schizo-
phrenia. This finding justifies the need to examine the
relationship between toxoplasmosis and schizophrenia
with pre-clinical and clinical trials aimed to improve
prevention and treatment programs in patients with
psychiatric illness [71,72]. On the other hand, a meta-
analysis of latent Toxoplasma gondii infection in immuno-
competent hosts and cryptogenic epilepsy showed a strong
association between seroprevalence rates for toxoplas-
mosis and prevalence rates of epilepsy. If an etiological
connection can be proven, it would have implications
for the implementation of prevention and treatment
strategies for Toxoplasma disease [73].
Cat owners and slaughterhouse workers presented both
a CP and WP of 21.88% each. This may be because only
five studies with 501 individuals with this attribute were
analyzed. Regarding patients with nonrelated comor-
bidity, WP was 12.28%, lower than in the general
population. Three groups were studied with STA and
four more from Durango had the lowest prevalence in
the country, which may show that their comorbidity
was not related to the risk of infection.
Another important factor is the difference in the preva-
lence of T. gondii infections due to the sensitivity and spe-
cificity of diagnostic tests, since there are several methods
to identify and evaluate antibodies in individuals who
were infected by the parasite. Over time, at least four dif-
ferent diagnostic assays have been used worldwide that
range from the lowest specificity and sensitivity like the
STA progressing on to the SF Dye Test and other similar
tests up to the improved ELISA (Table 2) [7,74].
In regards to the analysis of the study groups adjusted
by risk factors (with or without) and diagnostic test, we
found that only those tested by ELISA showed a WP of
17.66% in the risk factor groups against a WP of 8.92%
in the groups without risk factors. However, with the
other methods, both crude and weighted prevalence
were reduced; however, the number of studied indivi-
duals was higher. This analysis demonstrates that the
prevalence varies according to the diagnostic method
and by the number of individuals tested in each study
group (Figure 2).
The epidemiological behavior of Toxoplasma infection
showed a negative slope of −0.1%/year, which representedan accumulated decrement of nearly 6% in the prevalence
of infection in Mexico after 60 years. This may suggest
that we have not paid enough attention to T. gondii
infection as a public health problem though it tends to
decrease. However, another key issue is that if the studies
carried out in the first 10 years had been tested with
ELISA then the decrement would have been even lower
(Figure 2).
In this study, stratification of studies based on molecu-
lar assays was not feasible because none was reported.
However, genotyping has been reported in other Latin
American populations, such as Colombia where a viru-
lent strain (LD100 of 10 tachyzoites) was identified as
clonal type 1 (CIBMUQ/HDC) [75]. Additionally, in an-
other study, the GRA6 type I/III profile was the most
frequent among asymptomatic cases (68/148, 45.9%) and
in severe multi visceral cases (2/4, 50%). Furthermore,
GRA6 type II, was found in one case of congenital toxo-
plasmosis, one case of severe multi visceral infection, one
case of ocular infection, and in five cases (5/148,3.4%) of
asymptomatic patients [76]. Further studies based on
genetic-based diagnostic assays will be relevant in the
future, since Toxoplasma gondii isolates from Latin
America have mixed/ recombinant genetic structure.
A 6% decrement in the prevalence of Toxoplasma in-
fection after 60 years of studies was detected. This decre-
ment is quite low after a relatively long period, contrary
to what has been reported in the United States, with a
14% decrement in only one decade [77]. Therefore, our
data warrants that researchers must pay more attention
to this disease and to communicate to the medical com-
munity the need of improvement of the prevention stra-
tegies, together with effective diagnostic testing and
management of patients in high risk of infection such as
immunocompromised patients and pregnant women.
Further research is still required to understand and
clarify the role of T. gondii in its diverse routes of trans-
mission, as well as to design better control measures
that focus on minimizing the risk of infection. The pur-
pose of such studies should be to aid in the monitoring
of changes in the epidemiology of T. gondii infection,
and to strengthen educational efforts in order to avoid
the transmission of infection in populations that cannot
be controlled by drugs alone.Implications for research
A crucial factor is the difference in the prevalence of
T. gondii infections due to the sensitivity and specificity
of the diagnostic tests, since there are several methods to
identify and evaluate antibodies in individuals who were
infected by the parasite. At least four different diagnostic
assays have been used in this study, that range from the
lowest specificity and sensitivity like the CF, progressing
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improved ELISA.
Conclusion
In conclusion, to the best of our knowledge, this is the
first study that provides a comprehensive view of the epi-
demiological situation on the prevalence of T. gondii
infection among the adult Mexican population. It pro-
vides not only epidemiologic evidence relevant to Mexico,
but to other countries in the Americas and worldwide
as well, where it has been documented that T. gondii
prevalence is shifting, related to regional climate changes
among other factors. In this study, the major risk groups
with Toxoplasma infection were women with miscarriages,
immunocompromised patients, mentally-ill patients and
other risk groups. Noteworthy was the psychiatric patients
group, since T.gondii can cause serious damage to the
central nervous system.
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